{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:50:13Z","timestamp":1793065813902,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.pharma.2026.06.008","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T23:45:52Z","timestamp":1782431152000},"page":"988-997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of GLP-1 receptor agonists on periodontal tissue: An interdisciplinary evidence mapping\u00a0\u2013\u00a0scoping review"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1287-6451","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Henriques","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1816-0706","authenticated-orcid":false,"given":"Artur Villas Boas","family":"Weckwerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5640-9292","authenticated-orcid":false,"given":"Adriana Campos Passanezi","family":"Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6782-8596","authenticated-orcid":false,"given":"Carla Andreoti","family":"Damante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0405-3500","authenticated-orcid":false,"given":"Carlos Ferreira dos","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3720-1183","authenticated-orcid":false,"given":"Carlos Antonio","family":"Negrato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2026.06.008_bib0005","series-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2025"},{"key":"10.1016\/j.pharma.2026.06.008_bib0010","series-title":"Global oral health status report: towards universal health coverage for oral health by 2030","author":"World Health Organization","year":"2022"},{"key":"10.1016\/j.pharma.2026.06.008_bib0015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/jcpe.12808","article-title":"Scientific evidence on the links between periodontal diseases and diabetes: consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International Diabetes Federation and the European Federation of Periodontology","volume":"45","author":"Sanz","year":"2018","journal-title":"J Clin Periodontol"},{"key":"10.1016\/j.pharma.2026.06.008_bib0020","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/jcpe.12803","article-title":"An update on the evidence for pathogenic mechanisms that may link periodontitis and diabetes","volume":"45","author":"Polak","year":"2018","journal-title":"J Clin Periodontol"},{"key":"10.1016\/j.pharma.2026.06.008_bib0025","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/jre.12518","article-title":"Advanced glycation end-products increase IL-6 and ICAM-1 expression via RAGE, MAPK and NF-kB pathways in human gingival fibroblasts","volume":"53","author":"Nonaka","year":"2018","journal-title":"J Periodontal Res"},{"key":"10.1016\/j.pharma.2026.06.008_bib0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41368-021-00116-6","article-title":"Diabetes fuels periodontal lesions via GLUT1-driven macrophage inflammaging","volume":"13","author":"Wang","year":"2021","journal-title":"Int J Oral Sci"},{"key":"10.1016\/j.pharma.2026.06.008_bib0035","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/jre.12912","article-title":"Hyperglycemia modulates M1\/M2 macrophage polarization via reactive oxygen species overproduction in ligature-induced periodontitis","volume":"56","author":"Zhang","year":"2021","journal-title":"J Periodontal Res"},{"key":"10.1016\/j.pharma.2026.06.008_bib0040","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S2213-8587(18)30038-X","article-title":"Systemic effects of periodontitis treatment in patients with type 2 diabetes: a 12 month, single-centre, investigator-masked, randomised trial","volume":"6","author":"D\u2019Aiuto","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pharma.2026.06.008_bib0045","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/jcpe.12858","article-title":"Benefits of non-surgical periodontal treatment in patients with type 2 diabetes mellitus and chronic periodontitis: a randomized controlled trial","volume":"45","author":"Mauri-Obradors","year":"2018","journal-title":"J Clin Periodontol"},{"key":"10.1016\/j.pharma.2026.06.008_bib0050","doi-asserted-by":"crossref","first-page":"e0188171","DOI":"10.1371\/journal.pone.0188171","article-title":"The effects of non-surgical periodontal treatment on glycemic control, oxidative stress balance and quality of life in patients with type 2 diabetes: a randomized clinical trial","volume":"12","author":"Mizuno","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.pharma.2026.06.008_bib0055","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/dom.14399","article-title":"Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomised controlled trials","volume":"23","author":"Bray","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharma.2026.06.008_bib0060","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Muller","year":"2019","journal-title":"Mol Metab"},{"key":"10.1016\/j.pharma.2026.06.008_bib0065","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.yexcr.2017.09.018","volume":"360","author":"Wu","year":"2017","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.pharma.2026.06.008_bib0070","doi-asserted-by":"crossref","first-page":"110523","DOI":"10.1016\/j.biopha.2020.110523","article-title":"Liraglutide, a glucagon-like peptide-1 receptor agonist, suppresses osteoclastogenesis through the inhibition of NF-kB and MAPK pathways via GLP-1R","volume":"130","author":"Li","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pharma.2026.06.008_bib0075","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cmet.2023.11.009","article-title":"Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation","volume":"36","author":"Wong","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharma.2026.06.008_bib0080","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.cmet.2024.05.001","article-title":"Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule","volume":"36","author":"Ben Nasr","year":"2024","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharma.2026.06.008_bib0085","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"Peters","year":"2020","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.pharma.2026.06.008_bib0090","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharma.2026.06.008_bib0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int J Soc Res Methodol"},{"key":"10.1016\/j.pharma.2026.06.008_bib0100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1748-5908-5-69","article-title":"Scoping studies: advancing the methodology","volume":"5","author":"Levac","year":"2010","journal-title":"Implement Sci"},{"key":"10.1016\/j.pharma.2026.06.008_bib0105","doi-asserted-by":"crossref","first-page":"8843310","DOI":"10.1155\/2020\/8843310","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide ameliorates the development of periodontitis","volume":"2020","author":"Sawada","year":"2020","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.pharma.2026.06.008_bib0110","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1902\/jop.2015.150278","article-title":"Exenatide and sitagliptin decrease interleukin 1beta, matrix metalloproteinase 9, and nitric oxide synthase 2 gene expression but does not reduce alveolar bone loss in rats with periodontitis","volume":"86","author":"Moraes","year":"2015","journal-title":"J Periodontol"},{"key":"10.1016\/j.pharma.2026.06.008_bib0115","doi-asserted-by":"crossref","first-page":"8260111","DOI":"10.1155\/2022\/8260111","article-title":"Therapeutic potential of liraglutide for diabetes-periodontitis comorbidity: killing two birds with one stone","volume":"2022","author":"Yang","year":"2022","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.pharma.2026.06.008_bib0120","doi-asserted-by":"crossref","first-page":"103310","DOI":"10.1016\/j.jdent.2020.103310","article-title":"Liraglutide regulates bone destruction and exhibits anti-inflammatory effects in periodontitis in vitro and in vivo","volume":"94","author":"Zhang","year":"2020","journal-title":"J Dent"},{"key":"10.1016\/j.pharma.2026.06.008_bib0125","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/jre.12607","article-title":"The effect of liraglutide on the proliferation, migration, and osteogenic differentiation of human periodontal ligament cells","volume":"54","author":"Pang","year":"2019","journal-title":"J Periodontal Res"},{"key":"10.1016\/j.pharma.2026.06.008_bib0130","doi-asserted-by":"crossref","first-page":"107495","DOI":"10.1016\/j.jdiacomp.2019.107495","article-title":"GLP-1 inhibits PKCbeta2 phosphorylation to improve the osteogenic differentiation potential of hPDLSCs in the AGE microenvironment","volume":"34","author":"Wang","year":"2020","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.pharma.2026.06.008_bib0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.archoralbio.2018.03.014","article-title":"Exendin-4 relieves the inhibitory effects of high glucose on the proliferation and osteoblastic differentiation of periodontal ligament stem cells","volume":"91","author":"Guo","year":"2018","journal-title":"Arch Oral Biol"},{"key":"10.1016\/j.pharma.2026.06.008_bib0140","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.bbagen.2016.05.003","article-title":"Mechanical stress regulates osteogenic differentiation and RANKL\/OPG ratio in periodontal ligament stem cells by the Wnt\/beta-catenin pathway","volume":"1860","author":"Zhang","year":"2016","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.pharma.2026.06.008_bib0145","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/jcpe.13798","article-title":"Human gingival mesenchymal stem cell-derived exosomes cross-regulate the Wnt\/beta-catenin and NF-kB signalling pathways in the periodontal inflammation microenvironment","volume":"50","author":"Hu","year":"2023","journal-title":"J Clin Periodontol"},{"key":"10.1016\/j.pharma.2026.06.008_bib0150","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.stemcr.2016.02.002","article-title":"Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through beta-catenin","volume":"6","author":"Meng","year":"2016","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.pharma.2026.06.008_bib0155","doi-asserted-by":"crossref","first-page":"e3168","DOI":"10.1002\/dmrr.3168","article-title":"Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"35","author":"Cheng","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.pharma.2026.06.008_bib0160","doi-asserted-by":"crossref","first-page":"3361309","DOI":"10.1155\/2021\/3361309","article-title":"Effects of GLP-1 receptor agonists on bone mineral density in patients with type 2 diabetes mellitus: a 52-week clinical study","volume":"2021","author":"Cai","year":"2021","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.pharma.2026.06.008_bib0165","doi-asserted-by":"crossref","first-page":"115197","DOI":"10.1016\/j.bone.2019.115197","article-title":"Bone resorption is unchanged by liraglutide in type 2 diabetes patients: a randomised controlled trial","volume":"132","author":"Hygum","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.pharma.2026.06.008_bib0170","doi-asserted-by":"crossref","first-page":"e2416775","DOI":"10.1001\/jamanetworkopen.2024.16775","article-title":"Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial","volume":"7","author":"Jensen","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.pharma.2026.06.008_bib0175","doi-asserted-by":"crossref","first-page":"e0201855","DOI":"10.1371\/journal.pone.0201855","article-title":"High glucose-induced oxidative stress impairs proliferation and migration of human gingival fibroblasts","volume":"13","author":"Buranasin","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.pharma.2026.06.008_bib0180","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1210\/en.2018-00004","article-title":"GLP-1 receptor expression within the human heart","volume":"159","author":"Baggio","year":"2018","journal-title":"Endocrinology"},{"issue":"Suppl. 22","key":"10.1016\/j.pharma.2026.06.008_bib0185","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/jcpe.13232","article-title":"The adjunctive use of host modulators in non-surgical periodontal therapy. A systematic review of randomized, placebo-controlled clinical studies","volume":"47","author":"Donos","year":"2020","journal-title":"J Clin Periodontol"},{"key":"10.1016\/j.pharma.2026.06.008_bib0190","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/JPER.19-0613","article-title":"Omega-3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: randomized clinical trial","volume":"91","author":"Castro dos Santos","year":"2020","journal-title":"J Periodontol"},{"key":"10.1016\/j.pharma.2026.06.008_bib0195","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00784-019-03005-9","article-title":"Novel 20% doxycycline-loaded PLGA nanospheres as adjunctive therapy in chronic periodontitis in type-2 diabetics: randomized clinical, immune and microbiological trial","volume":"24","author":"Lecio","year":"2020","journal-title":"Clin Oral Investig"},{"key":"10.1016\/j.pharma.2026.06.008_bib0200","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12967-018-1678-1","article-title":"Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail","volume":"16","author":"Pound","year":"2018","journal-title":"J Transl Med"},{"key":"10.1016\/j.pharma.2026.06.008_bib0205","doi-asserted-by":"crossref","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.pharma.2026.06.008_bib0210","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2026.06.008_bib0215","doi-asserted-by":"crossref","first-page":"101737","DOI":"10.1016\/j.eclinm.2022.101737","article-title":"Effects of once-weekly semaglutide 2.4\u00a0mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials","volume":"55","author":"Verma","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.pharma.2026.06.008_bib0220","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2026.06.008_bib0225","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2026.06.008_bib0230","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2026.06.008_bib0235","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/dom.14553","article-title":"The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis","volume":"24","author":"Wilson","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.pharma.2026.06.008_bib0240","doi-asserted-by":"crossref","first-page":"e140532","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926001045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926001045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:42:47Z","timestamp":1792744967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450926001045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0003450926001045"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2026.06.008","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of GLP-1 receptor agonists on periodontal tissue: An interdisciplinary evidence mapping\u00a0\u2013\u00a0scoping review","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2026.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}